• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Editor's Pick

Hawley blasts FDA approval of new abortion drug, cites safety and trust concerns

by October 2, 2025
written by October 2, 2025

Sen. Josh Hawley, R-Mo., accused the Food and Drug Administration (FDA) of endangering women’s health, saying the agency approved another chemical abortion drug without the thorough safety review it had promised.

Hawley argued the move shows both regulatory failure and the influence of a company that refuses to define ‘woman’ in its materials.

‘This is shocking. FDA has just approved ANOTHER chemical abortion drug, when the evidence shows chemical abortion drugs are dangerous and even deadly for the mother. And of course 100% lethal to the child,’ he wrote on X on Thursday afternoon.

Hawley added, ‘FDA had promised to do a top-to-bottom safety review of the chemical abortion drug, but instead they’ve just greenlighted new versions of it for distribution. I have lost confidence in the leadership at FDA.’

Evita Solutions describes its mission as to ‘normalize abortion’ and make it ‘accessible to all.’ On its website, the company says it ‘believes that all people should have access to safe, affordable, high-quality, effective, and compassionate abortion care, regardless of their race, sex, gender, age, sexuality, income, or where they live.’

It adds, ‘We know that you can make the best choice for your body.’

According to the FDA, Evita received approval in a Sept. 30 letter obtained by Reuters.

In an interview with Fox News Digital, Hawley said the FDA’s decision was even more troubling given that its promised safety review has barely begun.

‘I just, I can’t figure out what’s happening at the FDA. I’m totally baffled by it,’ Hawley said.

Fox News Digital has reached out to the FDA and Evita Solutions for comment on the matter.

In another post, Hawley blasted the FDA for partnering with a company that ‘doesn’t even believe there is such a thing as a ‘woman.’’

Evita Solutions now joins GenBioPro in producing the generic version of Mifepristone, the abortion pill originally made by Danco Laboratories. Mifepristone blocks progesterone, a hormone needed to sustain pregnancy, and is followed by misoprostol to complete the process.

The approval comes as abortion drugs face mounting opposition from conservative lawmakers, religious organizations, and pro-life groups.

Religious groups like Inspire Investing and Alliance Defending Freedom have campaigned against the drug, while the Restoration of America Foundation (ROAF) has pressed lawmakers for accountability.

Last month, ROAF called on the Senate Finance Committee to hold Health and Human Services Secretary Robert F. Kennedy Jr. accountable at a hearing, demanding answers about the removal of safety protocols for the abortion pill Mifepristone.

In a letter obtained by Fox News Digital, ROAF warned that the rollback leaves women more vulnerable and shifts costs to taxpayers. The group said the Biden-era changes endanger women by allowing abortion pills to be prescribed via telehealth and sent through the mail.

Hawley said the FDA should restore the safeguards put in place under the Trump administration.

‘What needs to happen is the FDA needs to get in line with the president’s policy and put back into place the safety regulations President Trump had. Ditch the Biden approach and go back to President Trump’s approach,’ Hawley said.

Under the Biden administration, the FDA for the first time allowed telehealth prescribing and mail-order delivery of abortion pills. Previously, the agency required Mifepristone to be dispensed in person to screen for complications such as ectopic pregnancy.

Fox News Digital’s Jasmine Baehr and Reuters contributed to this report.

This post appeared first on FOX NEWS
0 comment
0
FacebookTwitterPinterestEmail

previous post
The agency staff Vought might recommend cutting and whether the cuts will be permanent
next post
Federal judge to sentence Justice Brett Kavanaugh’s attempted assassin

related articles

Plan to end government shutdown survives key House...

February 3, 2026

Planned Parenthood drops lawsuit challenging Trump administration’s Medicaid...

February 3, 2026

Clintons agree to testify after House threatens contempt...

February 3, 2026

EXCLUSIVE: Gabbard outlines election security assessment, presence at...

February 3, 2026

House GOP majority shrinks to just one vote...

February 3, 2026

DOJ removes Ed Martin from Trump admin’s Weaponization...

February 3, 2026

Costa Rica swings right as voters embrace tough-on-crime...

February 3, 2026

Trump undercuts GOP push to attach SAVE Act...

February 3, 2026

Fox News Digital report spurs 22 AGs to...

February 3, 2026

Schumer nukes GOP push for ‘Jim Crow-era’ voter...

February 2, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Legal challenges on administrative reach expected in Trump’s deregulatory scheme, experts say

    November 27, 2024
  • Top liquor distributor favored Costco and Kroger over small businesses, FTC says

    December 13, 2024
  • The US is not ready for a nuclear showdown with China, key conservatives warn Trump

    March 31, 2025
  • Tim Cook to join Trump at White House for Apple investment announcement

    August 7, 2025
  • Starbucks Stock: Exploring Partnerships in China

    November 21, 2024

Popular Posts

  • 1

    District judges’ orders blocking Trump agenda face hearing in top Senate committee

    April 2, 2025
  • 2

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 3

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 4

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 5

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024

Categories

  • Economy (829)
  • Editor's Pick (7,763)
  • Investing (935)
  • Stock (969)

Latest Posts

  • EURGBP and EURCHF: EURCHF fell at a new all-time low

    August 5, 2024
  • Senate to hold final vote on RFK Jr nomination to serve as Trump’s Health secretary

    February 13, 2025
  • Saudi fighter jets escort Air Force One as Trump arrives to meet crown prince

    May 13, 2025

Recent Posts

  • New York Stock Exchange: Dow Jones Down 1.29%

    July 19, 2024
  • Hamas, who sparked war with Israel, says Trump’s rebuild Gaza plan is a ‘Recipe for creating chaos’

    February 5, 2025
  • Trump campaign says it’s ‘well-positioned to prosecute the case’ against Kamala Harris

    July 24, 2024

Editor’s Pick

  • Harris launched ‘dark-arts operation’ against opponents for VP spot in 2020, new book claims

    April 9, 2025
  • Intel offloads stake in UK chip designer Arm amid restructuring push

    August 14, 2024
  • Trump nominates Waltz for high-level post after ousting him as national security advisor

    May 1, 2025
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock